Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial

Summary Background Docetaxel and gemcitabine are active against breast cancer. The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined with weekly gemcitabine in patients with chemotherapy-pretreated metastatic breast cancer Patients and methods Thirty-nine patients were enrolled, of whom thirty had received prior chemotherapy in the adjuvant setting, seven for metastatic disease, and two for both, including prior anthracycline in 33 patients. Treatment was gemcitabine 800 mg/m2 days 1, 8, 15 and docetaxel 100 mg/m2 on day 1, with cycles repeated every four weeks Results Response rate was 79% (95% confidence interval (CI) 63%-91%), with 2 complete and 29 partial responses Twenty-five of the responders remained progression-free for more than six months Median survival was 24.5 months. Delivered dose intensity of gemcitabine was lower than expected (63% of planned). The predominant hematologic toxicity was grade 4 neutropenia in 36 patients, complicated by fever in three patients With the exception of asthenia, severe non-hematological toxicities were infrequent Conclusions Monthly docetaxel, combined with weekly gemcitabine, has significant but manageable hmatologic toxicity Despite frequent dose adjustments, this doublet is very active in metastatic breast cancer, producing a high proportion of durable responses associated with favorable survival